BioNexus Gene Lab Corp Common stock (BGLC) — Cash Flow Reinvestment Rate
BioNexus Gene Lab Corp Common stock (BGLC) has a Cash Flow Reinvestment Rate of 0.14x as of December 2022, reinvesting $66.93K (capex $17.03K plus investments $-49.90K) from operating cash flow of $474.47K. Explore BioNexus Gene Lab Corp Common stock (BGLC) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BioNexus Gene Lab Corp Common stock Cash Flow Reinvestment Rate (2017–2022)
Historical reinvestment intensity for BioNexus Gene Lab Corp Common stock across 4 annual periods. Also explore balance sheet size of BioNexus Gene Lab Corp Common stock for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for BioNexus Gene Lab Corp Common stock (2017–2022)
Year-by-year capital reinvestment analysis for BioNexus Gene Lab Corp Common stock. For live market cap and broader valuation context, see BioNexus Gene Lab Corp Common stock (BGLC) total market value.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.93x | $504.67K | $544.03K | $54.17K | ▼ -98.3% |
| 2021 | 55.96x | $512.61K | $9.16K | $3.16K | ▲ +6082.7% |
| 2020 | 0.91x | $500.19K | $552.68K | $421.62K | ▼ -1.1% |
| 2017 | 0.92x | $326.90K | $357.22K | $314.82K | — |